Pfizer Expands Access to HIV Rx Maraviroc As Monogram Tests for CCR5-Tropism | GenomeWeb
Pfizer will make available its investigational HIV drug Maraviroc to patients with limited treatment options due to drug resistance and intolerance to therapy, the company said last week.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.